Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2019 09:18 ET | Source: Nemaura Medical Inc

Nemaura Medical Announces Exclusive License and Supply Agreement for SugarBEAT® in the GCC Region

Loughborough, England , March 12, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – March 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of...
February 12, 2019 09:15 ET | Source: Nemaura Medical Inc

Nemaura Reports Third Quarter 2018 Financial Results

Loughborough, England – Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible...
February 11, 2019 08:00 ET | Source: Nemaura Medical Inc

Nemaura Announces Dr. Fred Schaebsdau to Lead Strategy and Business Development

Dr. Schaebsdau to Advance European Launch of SugarBEAT® Continuous Glucose Monitor Nemaura Preparing U.S. FDA 510(k) Submission Loughborough, England – February 11, 2019 – Nemaura Medical,...
February 07, 2019 09:00 ET | Source: Nemaura Medical Inc

Nemaura Medical Announces Grant of U.S. Patent for SugarBEAT® Glucose Sensing Algorithm

Loughborough, England – February 7, 2019 – Nemaura Medical Inc. (NASDAQ: NMRD) nemauramedical.com, a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable...
January 17, 2019 09:00 ET | Source: Nemaura Medical Inc

Nemaura Medical Announces Improvement to SugarBEAT® Continuous Glucose Monitor

Loughborough, England –Nemaura Medical, Inc. (NASDAQ: NMRD) nemauramedical.com a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible...
December 21, 2018 08:00 ET | Source: Nemaura Medical Inc

Nemaura Announces Completion of Key Stages of Technical File Review for SugarBEAT® CE Mark Approval

LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...
December 19, 2018 08:00 ET | Source: Nemaura Medical Inc

Nemaura to Host Investor Webinar on December 21 to Provide Update on Recent Developments

LOUGHBOROUGH, England - Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...
December 18, 2018 09:00 ET | Source: Nemaura Medical Inc

Nemaura Publishes Positive Data from SugarBEAT® FDA Clinical Trial

LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...
December 18, 2018 08:40 ET | Source: Nemaura Medical Inc

Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering

LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by...
December 17, 2018 17:15 ET | Source: Nemaura Medical Inc

Nemaura Medical Announces Proposed Public Offering

LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by...